Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-NF2: Platform Trial for NF2-related Schwannomatosis
NCT07713745Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2026
- Primary completion
- Jun 2036
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib, luvometinib, serplulimab in neurofibromatosis type 2 (NF2), vestibular schwannoma (VS), schwannoma, meningioma, ependymoma, sponsored by Beijing Tiantan Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
selumetinibluvometinibserplulimab
03
Conditions
neurofibromatosis type 2 (NF2)vestibular schwannoma (VS)schwannomameningiomaependymoma
Beyond the preview
Go deeper on NCT07713745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713745.